Grant of share options
Nykode Therapeutics ASA (NYKD) · publisert 7. juli 2023 kl. 17:01 · vis på NewsWeb
Transaksjoner
| Person | Rolle | Type | Volum | Pris | Dato | ISIN | Handelsplass |
|---|---|---|---|---|---|---|---|
| Klaus Edvardsen | Chief Development Officer | Annet Tildeling | 193 322 | 0 NOK | 7. juli 2023 | NO0010714785 | Outside of trading venue |
| Michael Engsig | CEO | Annet Tildeling | 423 878 | 0 NOK | 7. juli 2023 | NO0010714785 | Outside of trading venue |
| Harald Gurvin | CFO | Annet Tildeling | 167 876 | 0 NOK | 7. juli 2023 | NO0010714785 | Outside of trading venue |
| Agnete B. Fredriksen | Chief Business Officer | Annet Tildeling | 154 446 | 0 NOK | 7. juli 2023 | NO0010714785 | Outside of trading venue |
| Mikkel W. Pedersen | Chief Scientific Officer | Annet Tildeling | 156 108 | 0 NOK | 7. juli 2023 | NO0010714785 | Outside of trading venue |
Vedlegg
- Attachment 230707.pdf (application/pdf, originaldokument)
Meldingstekst
Oslo, Norway, July 7, 2023 - A total of 2,510,889 share options have been granted to employees of Nykode Therapeutics ASA under the company’s share option scheme, of which 1,095,630 share options have been granted to primary insiders. The share options will have a strike price of NOK 28.47 per share, have a five-year term and will vest equally over a four-year vesting period.
Please see further details in attached document.